← All Posts
TRE
TREVI THERAPEUTICS, INC.
June 04, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1 |
Election of one Class I director to our Board of Directors to serve until the 2029 Annual Meeting of Stockholders |
✓ For(198.062)
|
| 2 |
Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. |
✓ For(198.062)
|
| 3 |
Approval, on an advisory basis, of the compensation paid to our named executive officers. |
✓ For(198.062)
|
| 4 |
Approval of the Trevi Therapeutics, Inc. Amended and Restated 2019 Stock Incentive Plan |
✓ For(198.062)
|
| 5 |
Approval of an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares |
✗ Against(198.062)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial